Systems, compositions and methods for treating diabetes

Abstract

This disclosure provides methods for treatment comprising co-administering insulin and glucagon to a subject, and co-formulations comprising insulin and glucagon.

1 - 24 . (canceled) 
     
     
         25 . A co-formulation comprising insulin at a concentration between about 1 mg/ml and about 10 mg/ml, and glucagon at a concentration between about 0.1 mg/ml and about 1 mg/ml, wherein the molar ratio of insulin:glucagon is between about 1:1 and about 6:1. 
     
     
         26 . The co-formulation of  claim 25 , wherein the molar ratio of insulin:glucagon is between about 1:1 and about 5:1. 
     
     
         27 . The co-formulation of  claim 25 , wherein the molar ratio of insulin:glucagon is between about 3:1 and about 6:1. 
     
     
         28 . The co-formulation of  claim 25 , wherein the molar ratio of insulin:glucagon is between about 3:1 and about 5:1. 
     
     
         29 . The co-formulation of  claim 25 , wherein the insulin is at a concentration between about 3 mg/ml and about 5 mg/ml, and the glucagon is at a concentration between about 0.1 mg/ml and about 0.8 mg/ml. 
     
     
         30 . The co-formulation of  claim 25 , further comprising a solvent that includes one or more aqueous solvents and one or more non-aqueous solvents. 
     
     
         31 . The co-formulation of  claim 30 , wherein between about 20% and about 60% of the solvent (v/v) consists of the one or more non-aqueous solvents, and no more than about 40% of the solvent (v/v) consists of the one or more aqueous solvents. 
     
     
         32 . The method of  claim 30 , wherein at least one non-aqueous solvent is dimethyl sulfoxide (DMSO) or N-methylpyrrolidone (NMP). 
     
     
         33 . The method of  claim 30 , wherein between about 10% and about 40% of the solvent is propylene glycol (PG), glycerol, or a combination of PG and glycerol.